drugset / Trial / NCT03367910
Fecal Microbiota Transplantation (FMT) for MDRO UTI
Phase 1/2
Completed
1 enrolled
Washington University School of Medicine
Centers for Disease Control and Prevention · collabDuke University · collabRebiotix Inc. · collabRush University · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to determine the safety and impact of fecal microbiota transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent urinary tract infection (UTI), and persistent multidrug resistant organism (MDRO) colonization of patients with a history of recurrent MDRO UTIs. This is an open label phase 1-2 study.
Timeline
- Start
- 2018-02-08
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBX2660 | Other / unclassified | 150 ml | Rectal |